<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01463644</url>
  </required_header>
  <id_info>
    <org_study_id>RP11-3588</org_study_id>
    <nct_id>NCT01463644</nct_id>
  </id_info>
  <brief_title>Mepolizumab in Chronic Obstructive Pulmonary Diseases (COPD) With Eosinophilic Bronchitis</brief_title>
  <official_title>Mepolizumab in COPD With Eosinophilic Bronchitis: A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Some patients with chronic obstructive pulmonary diseases (COPD) have large number of
      specific white blood cells called eosinophils in their airways. These cells are also
      responsible for causing episodes of worsened respiratory symptoms (exacerbations) and often
      cause irreversible damage to the airways . This subset of COPD patients often require oral
      steroids to bring down the number of eosinophils in their airways. Steroids have harmful
      effects on several of our body systems like bones, blood pressure, blood glucose control and
      can cause recurrent infections. Mepolizumab is a drug that specifically targets eosinophils
      reducing the number in the airway. This drug has been shown to be effective in decreasing
      exacerbation rates and time to exacerbation in asthma patients with eosinophils in their
      airways. Targeting eosinophils in COPD patients has been shown to reduce severe
      exacerbations. Hence it is likely that COPD patients with eosinophils in their airways will
      benefit similarly and have reduced rates and time to exacerbation.

      Study Hypothesis:Does mepolizumab decrease sputum eosinophils in patients with fixed airflow
      obstruction (COPD) and eosinophilic bronchitis?
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current standard of care of patients with moderate to severe COPD is a combination of
      inhaled corticosteroids, long-acting beta agonist and a long-acting muscarinic agonist (3-5).
      This treatment recommendation does not consider the heterogeneity of bronchitis in patients
      with COPD. A third of patients with COPD without asthma may have an eosinophilic bronchitis
      that is likely to respond to inhaled corticosteroids or prednisone. Approximately 1 in 5
      exacerbations are also likely to be associated with an eosinophilic exacerbation (6). This is
      unlikely to be controlled or prevented by the current recommendations that do not examine
      bronchitis at the time of exacerbations. None of the major clinical trials that have
      evaluated treatments that form the basis of current guidelines have examined bronchitis at
      the time of exacerbations.

      Quantitative cell counts in sputum provide a reliable method to assess bronchitis. Sputum can
      be safely induced with hypertonic saline even in patients with moderate and severe COPD.
      Similarly to asthma (7), the presence of eosinophils in sputum is a predictor of short-term
      response in forced expiratory volume at one second (FEV1) and quality of life to inhaled (8)
      and oral corticosteroids (9). A single study has demonstrated that normalizing eosinophils in
      sputum in patients with COPD reduces severe exacerbations and hospitalizations by
      approximately 60% (10). The relative risk reduction in this study is greater than that
      demonstrated by any study conducted so far in COPD. Long-term studies have not been
      conducted.

      Our recent experience with mepolizumab demonstrated that specifically targeting eosinophils
      in patient with severe asthma had a prednisone-sparing effect (11) and decrease exacerbations
      (11,12). In this study it also improved their lung function including in those patients with
      associated COPD. This is not surprising given that persistent airway eosinophilia can
      contribute to airway remodeling (13). Indeed, the improvement in FEV1 was associated with a
      decrease in sputum hyaluron (14) over the six month treatment period. Changes in lung
      function and symptoms have not been consistently observed in previous mepolizumab trials
      (12,15). This is clearly related to how precise the patients where phenotyped in terms of
      sputum eosinophilia. In studies that recruited patients who had persistent sputum
      eosinophilia, decrease in exacerbations were associated with improvements in FEV1 (16).

      It is thus likely that a specific treatment such as anti-IL5 directed against eosinophils
      would be superior to the current standard treatment in decreasing exacerbations in patients
      with COPD who continue to have eosinophils in their airway and whose airway disease has an
      eosinophil-driven component as evidenced by persistent airway eosinophilia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage decrease of sputum eosinophils from baseline</measure>
    <time_frame>6 months</time_frame>
    <description>The results will be expressed as absolute changes in percent counts and as fold changes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with a major exacerbation</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Chronic Obstructive Pulmonary Diseases</condition>
  <condition>Chronic Airways Limitation</condition>
  <condition>Bronchitis</condition>
  <arm_group>
    <arm_group_label>mepolizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mepolizumab</intervention_name>
    <description>This is an anti IL-5 which is given once a month intravenously at the dose of 750 mg.</description>
    <arm_group_label>mepolizumab</arm_group_label>
    <other_name>SB-240563</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>The placebo will consist of 100 mL normal saline solution (0.9%, 154 mmol/L sodium chloride).</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>Normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis: An established clinical history of COPD in accordance with the definition
             by the American Thoracic Society/European Respiratory Society as follows: Chronic
             obstructive pulmonary disease is a preventable and treatable disease state
             characterized by airflow limitation that is not fully reversible. The airflow
             limitation is usually progressive and is associated with an abnormal inflammatory
             response of the lungs to noxious particles or gases, primarily caused by cigarette
             smoking. Although COPD affects the lungs, it also produces significant systemic
             consequences

          -  Sputum eosinophils &gt; 3% at randomization and on at least one occasion in the past 2
             years. If this historic data is not available, documented improvement in FEV1 of at
             least 12% with a course of prednisone in the past 2 years will be used as a surrogate
             for the presence of airway eosinophilia

          -  FEV1/Vital Capacity (VC) &lt; 70% and FEV1 &lt; 60% of predicted normal values calculated
             using NHANES III reference equations at Screening Visit

          -  At least one major exacerbation requiring prednisone in the preceding 12 months. If
             patients are currently well controlled by optimizing their sputum cell counts
             (eosinophils &lt; 2%), they should have documented history of exacerbations when their
             eosinophilia was uncontrolled.

          -  A signed and dated written informed consent prior to study participation.

          -  Smoking History: Current or former cigarette smokers with a history of cigarette
             smoking of greater than 10 pack-years [number of pack years = (number of cigarettes
             per day/20) x number of years smoked (e.g., 20 cigarettes per day for 10 years, or 10
             cigarettes per day for 20 years]. Former smokers are defined as those who have stopped
             smoking for at least 6 months prior to Screening Visit

          -  Male or female adults. A female is eligible to enter and participate in the study if
             she is either of Non-child bearing potential or is of child bearing age and has a
             negative pregnancy test at screening, and agrees to acceptable contraceptive methods
             used consistently and correctly

        Exclusion Criteria:

          -  Current asthma (12% reversibility to a bronchodilator)

          -  Sputum eosinophils &lt; 3% on fluticasone (or equivalent) of 250Âµg bid.

          -  Inability to use salmeterol or tiotropium

          -  Significant co-morbidity that prevents from participating in the study

          -  Known bronchiectasis or immune deficiency disorders that would predispose the patients
             to recurrent infections.

          -  Pregnancy or intent to become pregnant and lactating females

          -  Drug or Alcohol Abuse: A known or suspected history of alcohol or drug abuse within 2
             years prior to Screening Visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Parameswaran Nair, MD,PhD,FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Professor of Medicine,Division of Respirology, McMaster University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Firestone Institute of Respiratory Health, St Joseph's Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2011</study_first_submitted>
  <study_first_submitted_qc>November 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2011</study_first_posted>
  <last_update_submitted>September 21, 2015</last_update_submitted>
  <last_update_submitted_qc>September 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mepolizumab</keyword>
  <keyword>COPD</keyword>
  <keyword>eosinophilic bronchitis</keyword>
  <keyword>exacerbation</keyword>
  <keyword>anti-interleukin 5 (IL5)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Bronchitis</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>June 6, 2017</submitted>
    <returned>October 30, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

